OpGen Q2 2023 Earnings Report

OpGen EPS Results

• Actual EPS: -$9.30
• Consensus EPS: -$7.10
• Beat/Miss: Missed by -$2.20
• One Year Ago EPS: -$26.00

OpGen Revenue Results

• Actual Revenue: $0.74 million
• Expected Revenue: $0.90 million
• Beat/Miss: Missed by -$160.00 thousand
• YoY Revenue Growth: N/A

OpGen Announcement Details

• Quarter: Q2 2023
• Date: 8/10/2023
• Time: After Market Closes

OpGen (NASDAQ:OPGN), a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.